PW01-039 – Long-term efficacy of anakinra in SoJIA patients

نویسندگان

  • A Naselli
  • J Tibaldi
  • A Accogli
  • A Buoncompagni
  • S Viola
  • S Signa
  • P Picco
  • A Ravelli
  • A Martini
  • M Gattorno
چکیده

Methods Since 2005, 34 SoJIA patients (19 M, 15 F) were treated with anakinra at the staring dose of 1-2 mg/kg/die. Complete response was defined as the absence of systemic and articular manifestations and normal acute phase reactants at follow-up, with anakinra as a monotherapy. Other patients were considered as partial responders (still in anakinra with evidence of disease activity) or non-responders (withdrawn of Anakinra due to inefficacy or severe side effects).

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.

BACKGROUND Anakinra treatment has been reported to be effective in some patients with systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease (AoSD). OBJECTIVES To assess the efficacy and the safety of anakinra treatment in SoJIA and AoSD. METHODS SoJIA and AoSD patients were treated with anakinra (1-2 mg/kg/day in children, 100 mg/day in adults); we analysed its e...

متن کامل

Early effects of Anakinra in corticosteroid naïve SOJIA patients

Interleukin-1R antagonist (anakinra) induces disease remission in about 50% of corticosteroid (CS) resistant cases of systemic onset JIA (SOJIA) [1,2]. Clinicians debate whether etanercept should still be tried first before giving anakinra to such patients. Another, more chalenging, issue is to start anakinra even in CS naïve SOJIA patients. We here report our first experiences of such an appro...

متن کامل

A Systemic-Onset Juvenile Idiopathic Arthritis Patient with Reduced Anakinra Treatment Admitted with an Attack.

Interleukin-1 plays an important role in the pathogenesis of systemic-onset juvenile idiopathic arthritis (SoJIA), and the use of anti-interleukin-1 therapy has been increasing. We report a case of a 14-year-old male patient with SoJIA. He was in remission with anakinra treatment for almost 2 years. When we extended the therapeutic range and decreased the dose (1 mg/kg twice a week), he develop...

متن کامل

Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients

Systemic Onset Juvenile Idiopathic Arthritis (SoJIA) is characterized by systemic inflammation and chronic arthritis. Intriguingly, the IL-18-NK cell axis seems to be disturbed in the majority of SoJIA patients. The observed NK cell dysfunction in SoJIA patients contributes to important features of the disease including the susceptibility for macrophage activation syndrome. Here we describe the...

متن کامل

Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF

Methods Sixteen patients affected by SoJIA (12 F, 4 M) were switched to Anakinra. Patients received Anakinra (in association with MTX) at the dose of 100 mg daily (> 50 kg) or at the dose of 1–2 mg/kg daily (< 50 kg). All patients failed previous DMARDS and TNF inhibitors. Paediatric patients were evaluated according to the ACR30 paediatric criteria. Adults were evaluated according to EULAR cri...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 11  شماره 

صفحات  -

تاریخ انتشار 2013